A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : anti-TNFalpha / anti-tumor necrosis factor alpha

[Related PubMed/MEDLINE]
Total Number of Papers: 252
[Display Entries]
100 entries :
     (Publication year, Descending)
100 entries :
     (Publication year, Ascending)
>> all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   anti-TNFalpha  (>> Co-occurring Abbreviation)
Long Form:   anti-tumor necrosis factor alpha
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Cell-centred meta-analysis reveals baseline predictors of anti-TNFalpha non-response in biopsy and blood of patients with IBD. AUC, CCL7, CCR2, TREM-1
2019 Current new challenges in the management of ulcerative colitis. UC
2019 Efficacy of Combination Antibiotic Therapy for Refractory Pediatric Inflammatory Bowel Disease. IBD, IBD-U, IQR, OR, PUCAI, UC
2019 Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children's immunity. IBD
2019 Neutrophil Extracellular Traps Sustain Inflammatory Signals in Ulcerative Colitis. CD, DSS, IL-1beta, LPMCs, NC, NETs, UC
2019 Radiologic parameters of ankylosing spondylitis patients treated with anti-TNF-alpha versus nonsteroidal anti-inflammatory drugs and sulfasalazine. AS, BASDAI, CRP, ESR, LL, NSAIDs, SSZ
2019 Relative risk of tuberculosis in patients with rheumatic diseases managed with anti-tumour necrosis factor-alpha therapy: A nationwide cohort study. PsA, RA, RDs, RR, TB
2019 The Influence of Preoperative Medications on Postoperative Complications in Patients After Intestinal Surgery for Crohn's Disease. CD, CI, RR
2018 A retrospective review of the persistence on bDMARDs prescribed for the treatment of rheumatoid arthritis in the Australian population. bDMARDs, cDMARD, RA, s.c
10  2018 Allergic and Immunologic Perspectives of Inflammatory Bowel Disease. CD, IBD, UC
11  2018 Axial Spondyloarthritis and Autosomal Dominant Polycystic Kidney Disease in Two Siblings: A Rare Cooccurrence. ADPKD, NSAIDs, SpA
12  2018 Biologic Drugs as Analgesics for the Management of Low Back Pain and Sciatica. anti-NGF
13  2018 Combining Anti-TNF-alpha and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series. VDZ
14  2018 Concentrations of infliximab and anti-drug antibodies in relation to clinical response in patients with rheumatoid arthritis. ADAs, IFX, RA
15  2018 Cost-Effectiveness of Different Strategies for the Treatment of Moderate-to-Severe Ulcerative Colitis. anti-AMi, ICER, JAKi, QALYs, UC, UK
16  2018 Effect of education and telephone counseling on adherence to treatment and challenges experienced in anti-TNF-alpha treatment: a pilot study. ---
17  2018 Efficacy of restarting anti-tumor necrosis factor alpha agents after surgery in patients with Crohn's disease. CD, OR
18  2018 Evaluation of sleep quality in patients with ankylosing spondylitis and efficacy of anti-TNF-alpha therapy on sleep problems: A polisomnographic study. AS, DA, PSG, PSQI, SQ
19  2018 Fecal Microbiota Signatures Are Associated with Response to Ustekinumab Therapy among Crohn's Disease Patients. AUC, CD, OTUs, UST
20  2018 First case of demyelinating polyneuropathy probably related to treatment with golimumab. ---
21  2018 Gene Signature-Based Approach Identified MEK1/2 as a Potential Target Associated With Relapse After Anti-TNFalpha Treatment for Crohn's Disease. CD, TUGs
22  2018 IBD-INFO Questionnaire: A Multicenter French Up-to-Date Survey of Patient Knowledge in Inflammatory Bowel Disease. CCKNOW, CCPKNOW, IBD
23  2018 Long-range PCR libraries and next-generation sequencing for pharmacogenetic studies of patients treated with anti-TNF drugs. CD, LR, NGS
24  2018 No effect of anti-TNF-alpha agents on the surgical stress response in patients with inflammatory bowel disease undergoing bowel resections: a prospective multi-center pilot study. IBD, LOS
25  2018 Pericardial Effusion due to Infliximab Therapy for Ulcerative Colitis. ---
26  2018 Pulmonary aspergillosis after treatment with infliximab in Still's disease and a literature review of Still's disease and pulmonary aspergillosis. ---
27  2018 Recommendation of using systemic anti-tumor necrosis factor-alpha for the treatment of noninfectious uveitis in Taiwan. NANIU
28  2018 Serious Adverse Events Associated with Anti-Tumor Necrosis Factor Alpha Agents in Pediatric-Onset Inflammatory Bowel Disease and Juvenile Idiopathic Arthritis in A Real-Life Setting. IBD, JIA, PYs, SAEs, TAILS
29  2018 Subclinical cardiac disease in ankylosing spondylitis. AS, csDMARDs, LV-GLS, NSAIDs
30  2018 Vedolizumab for inflammatory bowel disease: From randomized controlled trials to real-life evidence. CD, IBD, UC
31  2017 A Comparison of the Efficacy and Tolerability of the Treatments for Sciatica: A Network Meta-Analysis. ODI, SUCRA
32  2017 Anti-TNFalpha Treatment After Surgical Resection for Crohn's Disease Is Effective Despite Previous Pharmacodynamic Failure. ---
33  2017 Antitumor Necrosis Factor-alpha Therapy Associated with Inflammatory Bowel Disease: Three Cases and a Systematic Literature Review. ETN, IBD, JIA
34  2017 Biologic drugs as analgesics for the management of osteoarthritis. anti-NGF, OA
35  2017 Biologic Therapy for HLA-B27-associated Ocular Disorders. ---
36  2017 Comparison of the risk of infections in different anti-TNF agents: a meta-analysis. RA, RR
37  2017 Endoscopic Recurrence 6 Months After Ileocecal Resection in Children With Crohn Disease Treated With Azathioprine. CD, ICR
38  2017 Fatal Unusual Miliary Tuberculosis in which a Patient Developed Acute Respiratory Distress Syndrome Induced by Infliximab: An Autopsy Case Report. TB
39  2017 Guillain-Barre syndrome during adalimumab therapy for Crohns disease: coincidence or consequence? ---
40  2017 Higher 25-hydroxyvitamin D levels are associated with greater odds of remission with anti-tumour necrosis factor-alpha medications among patients with inflammatory bowel diseases. IBD
41  2017 Immune response to hepatitis B vaccination among people with inflammatory bowel diseases: A systematic review and meta-analysis. CI, HBV, IBD, MD, RR, RR
42  2017 Infliximab vs. adalimumab in Crohn's disease: results from 327 patients in an Australian and New Zealand observational cohort study. ---
43  2017 Is secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain Barre syndrome after anti-TNF-alpha treatment? Case report and literature review. AS, GBS, IL17A
44  2017 Long-term efficacy and safety of antitumour necrosis factor alpha treatment in rhupus: an open-label study of 15 patients. DAS28, RA, SLE, SLEDAI
45  2017 Postoperative Recurrence of Crohn's Disease: Pathophysiology, Diagnosis and Treatment. CD
46  2017 Reasons for Discontinuation and Adverse Effects of TNFalpha Inhibitors in a Cohort of Patients With Rheumatoid Arthritis and Ankylosing Spondylitis. AS, RA
47  2017 The evaluation of sleep quality and response to anti-tumor necrosis factor alpha therapy in rheumatoid arthritis patients. DA, PSG, PSQI, RA, SQ
48  2017 The incidence rate of surgical interventions in patients with Crohn's disease treated with anti-tumour necrosis factor biologics. CD, LOR
49  2017 The Influence of Adalimumab on the Healing ofApical Periodontitis in Ferrets. AP, RCT
50  2017 Trefoil factor-3 is not a useful marker of mucosal healing in Crohn's disease treated with anti-TNF-alpha antibodies. CD, MH, SES-CD, TFF-3
51  2017 Vaccinations in immunosuppressive-dependent pediatric inflammatory bowel disease. IBD
52  2016 A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-alpha and Anti-IL-12/23 Agents. ---
53  2016 Adalimumab Induced or Provoked MS in Patient with Autoimmune Uveitis: A Case Report and Review of the Literature. CNS, MRI, MS
54  2016 Anti-TNF Withdrawal in Inflammatory Bowel Disease. ---
55  2016 Anti-Tumour Necrosis Factor alpha Therapies and Inflammatory Bowel Disease Pregnancy Outcomes: A Meta-analysis. APOs, CAs, CI, IBD, LBW, PTB
56  2016 Body mass index and response to tocilizumab in rheumatoid arthritis: a real life study. BMI, RA, TCZ
57  2016 Comparison of Three Assays to Quantify Infliximab, Adalimumab, and Etanercept Serum Concentrations. ELISAs
58  2016 Compliance with risk management plan recommendations on laboratory monitoring of antitumor necrosis factor-alpha therapy in clinical practice. CXR, HBsAg, HCVAb, RMP, TB
59  2016 Disruption of Early Tumor Necrosis Factor Alpha Signaling Prevents Classical Activation of Dendritic Cells in Lung-Associated Lymph Nodes and Development of Protective Immunity against Cryptococcal Infection. DC, LALN
60  2016 Endoscopic Complete Remission of Crohn Disease After Anti-Tumor Necrosis Factor-alpha Therapy: CT Enterographic Findings and Their Clinical Implications. CR, CTE
61  2016 Malignancy risk of anti-tumor necrosis factor alpha blockers: an overview of systematic reviews and meta-analyses. IBD, RA
62  2016 Plasma, urine and ligament tissue metabolite profiling reveals potential biomarkers of ankylosing spondylitis using NMR-based metabolic profiles. AS, KEGG, VIP
63  2016 Postoperative Use of Anti-TNF-alpha Agents in Patients with Crohn's Disease and Risk of Reoperation-A Nationwide Cohort Study. ---
64  2016 Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa. HiSCR, HS
65  2016 Successful Discontinuation of Infliximab in a Refractory Case of Vasculo-Behcet Disease. IFX, vasculo-BD
66  2016 Survival and Effectiveness of Tumour Necrosis Factor-alpha Inhibitors in the Treatment of Plaque Psoriasis under Daily Life Conditions: Report from the Psoriasis Registry Austria. PsoRA
67  2016 The tuberculin skin test still matters for the screening of latent Tuberculosis infections among Inflammatory Bowel Disease patients. LTI, QFT-GIT, TST
68  2016 Treatment patterns and costs for anti-TNFalpha biologic therapy in patients with psoriatic arthritis. PPPM, PsA
69  2016 Update on the mechanisms of action of anti‑TNF-alpha antibodies and their clinical implications in inflammatory bowel disease. IBD
70  2015 AA amyloidosis treated with tocilizumab: case series and updated literature review. CRI, CRP, GFR, RA, REGATE, TCZ
71  2015 Acute Brucella melitensis M16 infection model in mice treated with tumor necrosis factor-alpha inhibitors. ---
72  2015 Antinuclear antibody (ANA) testing in patients treated with biological DMARDs: is it useful? ANA, dsDNA
73  2015 Association of serum VEGF with clinical response to anti-TNFalpha therapy for Crohn's disease. CD, VEGF
74  2015 Biofilm-associated bacterial amyloids dampen inflammation in the gut: oral treatment with curli fibres reduces the severity of hapten-induced colitis in mice. TLR, TNBS
75  2015 Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFalpha. CRP, EULAR, IL, miRNAs, PCR, RA, RF
76  2015 Clinical impact of concomitant immunomodulators on biologic therapy: Pharmacokinetics, immunogenicity, efficacy and safety. CD, IBD, NSAIDs, RA
77  2015 Combination of IgG N-glycomics and corresponding transcriptomics data to identify anti-TNF-alpha treatment responders in inflammatory diseases. CD
78  2015 Dengue Virus Infection with Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology without a High Level of Viremia in Mice. Abs, ADE, DENV, ICs
79  2015 Development of Heptylmannoside-Based Glycoconjugate Antiadhesive Compounds against Adherent-Invasive Escherichia coli Bacteria Associated with Crohn's Disease. AIEC, CD, HM, HM, IEC
80  2015 Disease characteristics and treatment patterns in veterans with rheumatoid arthritis and concomitant hepatitis C infection. HCV, OR, RA
81  2015 Efficacy, tolerability and safety of switching from etanercept to infliximab for the treatment of moderate-to-severe psoriasis: A multicenter, open-label trial (TANGO). HRQoL
82  2015 Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center. irAEs, OS, TTF
83  2015 In vivo evaluation of TNF-alpha in the lungs of patients affected by sarcoidosis. mAb
84  2015 Infliximab and adalimumab are stable in whole blood clotted samples for seven days at room temperature. ---
85  2015 Internuclear ophthalmoplegia associated with anti-TNFalpha medication. INO
86  2015 Long-term Outcomes and Risk Factors for Reoperation After Surgical Treatment for Gastrointestinal Crohn Disease According to Anti-tumor Necrosis Factor-alpha Antibody Use: 35 Years of Experience at a Single Institute in Korea. OR
87  2015 Mucosal relapse of visceral leishmaniasis in a child treated with anti-TNFalpha. ---
88  2015 New Trends in Inflammatory Bowel Disease. GI, IBD
89  2015 Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database. AEs, GI, IBD
90  2015 pANCA positivity predicts lower clinical response to infliximab therapy among patients with IBD. IBD, pANCA
91  2015 Real-life outcome of anti-tumor necrosis factor alpha in the ambulatory treatment of ulcerative colitis. ---
92  2015 The anti-TNF-alpha antibody infliximab inhibits the expression of fat-transporter-protein FAT/CD36 in a selective hepatic-radiation mouse model. ---
93  2015 The impact of preoperative serum anti-TNFalpha therapy levels on early postoperative outcomes in inflammatory bowel disease surgery. CD, IBD, OR, UC
94  2015 Vulval Crohn's disease: a clinical study of 22 patients. GCD, VCD
95  2015 Withdrawal of anti-tumour necrosis factor alpha therapy in inflammatory bowel disease. ---
96  2014 Acute and probable chronic Q fever during anti-TNFalpha and anti B-cell immunotherapy: a case report. RA
97  2014 Adalimumab regulates intracellular TNFalpha production in patients with rheumatoid arthritis. EULAR, RA
98  2014 Adherence and resource use among patients treated with biologic drugs: findings from BEETLE study. ---
99  2014 Anal tuberculosis complicating anti-TNFalpha therapy. ---
100  2014 Antitumor necrosis factor alpha is more effective than conventional medical therapy for the prevention of postoperative recurrence of Crohn's disease: a meta-analysis. CD, CI, OR